Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection

Alexa Glencer(University of California, San Francisco), Michael J. Campbell(University of California, San Francisco), Nola M. Hylton(University of California, San Francisco), Emma McCune(University of California, San Francisco), Harriet Rothschild(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco), Tristan Loveday(University of California, San Francisco), Jasmine Wong, Gregor Krings(Cleveland Clinic), Michael Alvarado(University of California, San Francisco)
npj Breast Cancer
May 25, 2021
10.1038/s41523-021-00267-z
Cited by 12

Related Papers

Whole-genome analysis informs breast cancer response to aromatase inhibition
|Nature|2012|1k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Comprehensive analysis of normal adjacent to tumor transcriptomes
|Nature Communications|2017|663
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
|Nature Medicine|2016|539